NCT05334316

Individualizing Corticosteroid Use in Pneumonia

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this study, researchers propose a unique (individualized) approach to steroid treatment seeking to give the right dose of steroid to the right patient and at the right time. This study seeks to compare usual care to an individualized steroid dosing strategy by testing a marker of inflammation in the blood called C- reactive protein (CRP). The overall goal is to reduce an individual's exposure to steroids and the risk of potential side effects thereby increasing the potential benefit of using steroids to control inflammation in pneumonia.

Conditions

• Pneumonia

Interventions

Type	Name	Description
DRUG	Dexamethasone	Administered intravenously or orally based on daily CRP values and CRP corticosteroid dosing algorithm

Timeline

• Start date: 2024-11-01
• Primary completion: 2026-12-01
• Completion: 2027-12-01
• First posted: 2022-04-19
• Last updated: 2025-08-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study